FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 29, 2009

THE FEMALE HEALTH COMPANY
(Exact name of registrant as specified in its charter)

Wisconsin
(State or other jurisdiction of incorporation)

1-13602
(Commission File Number)

39-1144397
(I.R.S. Employer I.D. Number)

515 North State Street
Suite 2225
Chicago, Illinois
(Address of Principal Executive Offices)

60654
(Zip Code)

312-595-9123
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

○ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

○ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

○ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

○ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 3 – Securities and Trading Markets

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On May 29, 2009, the Board of Directors of The Female Health Company (the "Company") approved the transfer of the listing of the Company's common stock to the NASDAQ Stock Market LLC ("NASDAQ") from NYSE Amex LLC ("AMEX") and authorized the Company's management to take all necessary action to effect the listing and trading of the common stock on NASDAQ and the delisting of the common stock from AMEX and the suspension of its trading thereon.

The Company expects that its common stock will cease trading on AMEX at the close of the market on June 8, 2009 and will commence trading on NASDAQ at the opening of the market on June 9, 2009.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE FEMALE HEALTH COMPANY

Date: May 29, 2009

BY /s/ Donna Felch
Donna Felch, Vice President and
Chief Financial Officer